Dianthus Therapeutics, Inc. /DE/ — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
This is a routine quarterly report (10-Q) for the period ending September 30, 2026, filed November 4, 2026. The filing metadata shows Dianthus Therapeutics is a biopharmaceutical company (SIC 2834) incorporated in Delaware with headquarters in New York. No specific financial results, deal announcements, corporate actions, or material events are detailed in the provided excerpt—only standard SEC filing boilerplate and document structure.
Why this rating
Standard quarterly disclosure with no concrete material event, deal, financing, or guidance change visible in excerpt. Routine filing.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.